In the multicenter, open-label, phase I clinical trial, 24 patients with w-AMD refractory to 3 or more anti-VEGF injections in the previous 6 months and a best-corrected visual acuity (BCVA) of 20/40 to 20/400 (Snellen equivalent) were injected with faricimab administered at single and multiple doses. The gene discussed is VEGFA; the disease is age-related macular degeneration.